Earnings season is here and we’ve got the first batch of big name companies reporting earnings this week with Taiwan Semiconductor (TSM), JP Morgan Chase (JPM), Wells Fargo (WFC), Bank of America (BAC), Goldman Sachs (GS), Johnson & Johnson (JNJ) and American Express (AXP) all set to report. In today’s article, we will look at how to use Barchart’s Screener’s to find option trade ideas for this earnings seasons. More News from Barchart Stock Screener The first step is to use the Stock Screener to find c ...

强生发布财报，第三季度销售额239.9亿美元，预计财年销售额为935亿美元至939亿美元。强生美股盘 前一度涨2.4%。 （文章来源：第一财经） ...

| | | 03 | | | --- | --- | --- | --- | | ($ in Millions, except EPS) | 2025 | 2024 | % Change | | Reported Sales | $23,993 | $22,471 | 6.8% | | Net Earnings | $5,152 | $2,694 | 91.2% | | EPS (diluted) | $2.12 | $111 | 91.0% | | | | Q3 | | | Non-GAAP* ($ in Millions, except EPS) | 2025 | 2024 | % Change | | Operational Sales1 | | | 5.4% | | Adjusted Operational Sales10 | | | 4.4% | | Adjusted Net Earnings14 | $6,801 | $5,876 | 15.7% | | Adjusted EPS (diluted)1/0 | $2.80 | $2.42 | 15.7% | | Free Cash Flow 6.7 ...

格隆汇10月14日｜强生(JNJ.US)预计财年销售额为935亿至939亿美元，此前预期为932亿至936亿美元。 ...

公司业绩表现 - 强生公司上调了全年销售展望 [1] - 公司在最近一个季度的处方药业务实现增长 [1] - 公司在最近一个季度的医疗器械业务实现增长 [1]

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend. ...

强生10月14日发布第三季度业绩显示，销售额239.9亿美元，同比增长6.8%；调整后每股收益2.80美 元，上年同期2.42美元。强生预计全年销售额935亿美元至939亿美元，此前预计932亿美元至936亿美 元，仍然预测调整后每股收益10.80美元至10.90美元。 来源：智通财经 ...

Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20... ...

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J& ...

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the "Company†) (NYSE: JNJ) today announced the Company's intent to ...